Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Kalaris Therapeutics Inc., 3 years.
Kalaris Therapeutics Inc.
Director · Chief Executive Officer
Nektar Therapeutics
Director
Chief executive roles
Kalaris Therapeutics Inc.
· Chief Executive Officer
Dates unknown
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Nektar Therapeutics May 23, 202587.8%
-
Kalaris Therapeutics Inc. May 11, 202387.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Nektar Therapeutics | Grant or award | +2,000 | — | — |
| Nov 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −8,706 | $0.55 | $4,788 |
| Nov 5, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −10,609 | $0.86 | $9,124 |
| Oct 21, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −9,752 | $0.78 | $7,607 |
| Oct 3, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −1,493 | $0.81 | $1,209 |
| Aug 20, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −5,390 | $0.74 | $3,989 |
| Aug 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −3,091 | $0.76 | $2,349 |
| Aug 5, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −10,847 | $0.73 | $7,918 |
| Jul 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −9,731 | $0.75 | $7,298 |
| Jul 2, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −1,489 | $0.72 | $1,072 |
| May 21, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −5,149 | $0.79 | $4,068 |
| May 17, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −3,075 | $0.75 | $2,306 |
| May 3, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −10,240 | $0.80 | $8,192 |
| Apr 19, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −9,601 | $0.75 | $7,201 |
| Apr 2, 2024 | Kalaris Therapeutics Inc. | Open-market sale | −1,533 | $0.77 | $1,180 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.